SCHEMBL14340922

SCHEMBL14340922

COC(=O)/C=C(\C)c1ccc(Br)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
DAO P14920 1/20 0.47
KMT2A Q03164 7/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GSK3B P49841 2/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
PPARG P37231 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
GAA P10253 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ESR1 P03372 1/20 0.41
MEN1 O00255 5/20 0.41
POLB P06746 3/20 0.41
NPC1 O15118 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14340921 0.81 DAO (0.57) CES2CES1DAOKMT2AALDH1A1
SCHEMBL9709670 0.75 TSHR (0.68) CES2CES1DAOKMT2AALDH1A1
SCHEMBL9709665 0.75 TSHR (0.68) CES2CES1DAOKMT2AALDH1A1
SCHEMBL70702 0.74 DAO (0.63) CES2CES1DAOKMT2AALDH1A1
SCHEMBL14340919 0.73 LMNA (0.51) KMT2AALDH1A1KDM4ETSHRNPSR1
SCHEMBL345568 0.72
SCHEMBL22390293 0.70 ALDH1A1 (0.47) CES2CES1KMT2AALDH1A1TSHR
SCHEMBL22390294 0.70 ALDH1A1 (0.47) CES2CES1KMT2AALDH1A1TSHR
SCHEMBL3347072 0.69 GSK3B (0.59) CES2CES1DAOKMT2AALDH1A1
SCHEMBL14624168 0.68 GSK3B (0.63) CES2CES1DAOKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-06 US disclosed
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281969-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment GPR119, FFAR1, HCAR1 CES2 1206/4885CES1 200/4885DAO 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.